Program
ACT100
A development code. Also written as “ACT100 Injection”.
Its studies are mostly in Lupus Erythematosus, Systemic, led by Xiamen Amoytop Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xiamen Amoytop Biotech | 11 open or running | phase 1since Feb 6, 2026 | Feb 6, 2026 | Mar 30, 2027phase 1 · NCT07408908 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 6, 2026First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT07408908 · 48 planned
Ahead
- Mar 30, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07408908
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07408908Lupus Erythematosus, Systemic | 1 | Not yet recruiting | Mar 30, 2027 | 48 |
How it is read
Names in the registry
- “ACT100 Injection”, 6 entries
Codes read as this program: ACT100.
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.